Brokerages Set AstraZeneca PLC (LON:AZN) PT at GBX 7,542.80

AstraZeneca PLC (LON:AZN) has earned an average rating of “Moderate Buy” from the seven analysts that are currently covering the firm, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is GBX 7,542.80 ($97.65).

A number of research firms have weighed in on AZN. Shore Capital reissued a “buy” rating on shares of AstraZeneca in a research note on Friday, March 7th. JPMorgan Chase & Co. restated an “overweight” rating on shares of AstraZeneca in a research report on Wednesday, February 19th. Finally, Berenberg Bank reiterated a “buy” rating and set a GBX 140 ($1.81) price target on shares of AstraZeneca in a report on Wednesday.

AstraZeneca Trading Up 1.5 %

Shares of AstraZeneca stock opened at £113.62 ($147.10) on Friday. AstraZeneca has a 1-year low of GBX 9,670 ($125.19) and a 1-year high of £133.88 ($173.33). The company has a debt-to-equity ratio of 73.83, a current ratio of 0.93 and a quick ratio of 0.59. The stock has a market cap of £218.61 billion, a P/E ratio of 31.14, a P/E/G ratio of 0.86 and a beta of 0.17. The stock’s 50 day simple moving average is £115.78 and its 200-day simple moving average is £112.80.

AstraZeneca Company Profile

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.